Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
The Supreme Court refused to hear Merck’s arguments on a hepatitis C patent, so the previous ruling in Gilead’s favor stands.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
This is according to two studies of real-world use of the hepatitis C regimen.
Stop me if you’ve heard this one before.
A second immunotherapy option is now available for hepatocellular carcinoma.
The pharmaceutical company’s grant-making arm is teaming up with Marshall Health to address areas hit hardest by opioids.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.
Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.
A recent analysis of data from a roster of clinical trials yielded reassuring findings for this group of women who have hepatitis C.
In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.